BFB 759
Alternative Names: BFB-759Latest Information Update: 29 Nov 2025
At a glance
- Originator Bluefin Biomedicine
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
Most Recent Events
- 15 Jul 2025 Phase-II clinical trials in Atopic dermatitis in USA (unspecified route) (NCT07105488)